|
Looking ahead to Gushan Environmental Energy Limited earnings; GU, ODC, KMGB, SIAL
| Traders watch earnings filings with particular interest, as changes in a company’s ratios can be a good indication whether a company is on the right track, or headed the wrong way. Gushan Environmental Energy Limited (GU) is scheduled to release its earnings results Wednesday. The company currently has an earnings per share ratio (EPS trailing twelve months) of - .14 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release. {loadposition link_newslink1} |
| | | {loadposition livevideopromo} | | | | | | {loadposition homeaccordion2}
| | | {loadposition contentad} | | | | | In the past three months, the stock has posted a -29.15% loss in terms of stock price. Over the same period, the Specialty Chemicals industry group has returned a combined .00% 0. So the eyes of investors turn to this new round of earnings. Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often. When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group. GU is in the Specialty Chemicals industry group where it competes for investor dollars with companies like Oil-Dri Corp. of America (ODC), which is set to release its earnings on 12/08 and last reported a 3.97% gain in quarter-over-quarter EPS. Another industry peer, KMG Chemicals Inc. (KMGB) released its earnings on 10/13 and last reported a 717.29% gain in QOQ EPS. Sigma-Aldrich Corporation (SIAL) is the stock with the biggest market cap in the Specialty Chemicals industry at $6.76B. It closed yesterday at $55.57 To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS. {loadposition link_nowtime}
{loadposition followus} |
-
News Feed
|
|
|
Looking ahead to Penford Corp. earnings; PENX, APFC, ALTI, SIAL
| Investors watch earnings releases keenly, as changes in a company’s performance can be a good indication whether a company is on the right track, or headed the wrong way. Penford Corp. (PENX) is scheduled to release its earnings results Friday. The company currently has an earnings per share ratio (EPS trailing twelve months) of -4.55 and investors are hoping to see that number change. Let’s take a look at the performance of the stock since its previous earnings release. {loadposition link_newslink1} |
| | | {loadposition livevideopromo} | | | | | | {loadposition homeaccordion2}
| | | {loadposition contentad} | | | | | In the past three months, the stock has posted a 2.45% gain in terms of stock price. Over the same period, the Specialty Chemicals industry group has returned a combined 13.84% gain. So the eyes of investors turn to this new round of earnings. Now, good earnings don’t always lead to higher stock prices, but keeping up on earnings is still a vital part of your fundamental stock analysis. Also note that companies often change earnings dates, so you should double-check them often. When looking at earnings, it’s very helpful to see how stocks compare to others in its industry group. And even though two stocks may not be direct competitors, many analysts and institutional investors still compare them and evaluate them relative to other stocks in their group. PENX is in the Specialty Chemicals industry group where it competes for investor dollars with companies like American Pacific Corp. (APFC), which released its earnings on 08/04 and last reported a -2922.82% decline in quarter-over-quarter EPS. Another industry peer, Altair Nanotechnologies, Inc. (ALTI) released its earnings on 11/05 and last reported a 1.96% gain in QOQ EPS. Sigma-Aldrich Corporation (SIAL) is the stock with the biggest market cap in the Specialty Chemicals industry at $6.74B. It closed yesterday at $55.36 To better understand how to evaluate earnings announcements and the affect they have on your portfolio, be sure to read Earnings Announcements and EPS. {loadposition link_nowtime}
{loadposition followus} |
-
News Feed
|
|
|
RxNews Recap for Tuesday 11-10-09
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Akorn, Inc. (NASDAQ:AKRX) a specialty pharmaceutical company, reported financial results for the third quarter ended September 30, 2009.Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics announced management will present at two upcoming conferences: the Lazard Capital Markets 6th Annual Healthcare Conference and the Windhover Therapeutic Area Partnerships event, where the Company’s Pralatrexate for Peripheral T-cell Lymphoma project was named as one of Windhover’s Top 10 interesting oncology projects.ArQule, Inc. (Nasdaq:ARQL) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 5:10 p.m. eastern time.Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.Biogen Idec Inc. (NASDAQ:BIIB) announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference will be webcast live, via the internet, on Tuesday, November 17, 2009 at 10:55a.m. EST.Elan Corporation, plc (NYSE:ELN) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference, on Tuesday, November 17, 2009 at; 9:55 a.m. Eastern Time and 2:55 p.m. GMT.Genoptix, Inc. (Nasdaq:GXDX), a specialized laboratory services provider, announced the Company's participation at the Lazard Capital ManaGement 6th Annual Healthcare Conference at The St. Regis Hotel in New York City on November 17-18, 2009.Impax Laboratories, Inc. (NASDAQ:IPXL) announced the Company will present at the Credit Suisse 18th Annual Healthcare Conference on Friday, November 13th, at 10:00 a.m. Mountain Standard time.ImmunoGen, Inc. (Nasdaq:IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.The positive mix lift expected as farmers choose to upgrade to next-generation technologies allows Monsanto Company (NYSE:MON) to reconfirm its commitment to double its 2007 gross profit in 2012, Monsanto President and CEO Hugh Grant will tell investors.Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, announced Gerald T. Proehl, president and chief executive officer, will make a presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009, at 10:55 a.m. Eastern time (7:55 a.m. Pacific time) at the St. Regis Hotel in New York City.S3 Investment Company, Inc. (OTC:SIVC) announced the company's wholly owned Redwood Capital subsidiary has received payment valued at over $500,000 in the form of cash and stock from the recent closing of a client equity offering.Sigma-Aldrich® (Nasdaq:SIAL) announced it has entered into an exclusive worldwide distribution agreement with Stemgent, Inc. to offer Stemgent's portfolio of lentivirus-based delivery systems for the generation of induced pluripotent stem (iPS) cells.Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab.Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid® (lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. Customers will begin receiving product on November 11, 2009.Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) announced holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued interest for approximately 4.8 million shares of the Company’s common stock, which is approximately 140,000 shares more than the number of shares into which the notes were convertible under their original terms.
-
BioMedReports.Com Sy...
|
